The US Food and Drug Administration (FDA) today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
The US Food and Drug Administration (FDA) today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS)—liposarcoma and leiomyosarcoma—that cannot be removed by surgery (unresectable) or is advanced (metastatic).
The US Food and Drug Administration (FDA) granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non–small-cell lung cancer (NSCLC) whose disease has progressed after other treatments, and with tumors that express a protein called PD-L1.
On September 30, 2015, the US Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.
The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeon’s Commission on Cancer (CoC).
Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business.
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib).
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).
New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib-Based Therapy from ASH 2012
Multiple myeloma (MM) accounts for 10% to 15% of all hematologic malignancies, and is the cause of 20% of the deaths that result from blood and bone cancers.
Novel therapies for patients with multiple myeloma (MM) continue to show improved outcomes for a population that as little as 8 years ago had few options.
Page 25 of 32
Results 241 - 250 of 315
Results 241 - 250 of 315